🦷 Xerostomia Saliva Flow Rate Risk Simulator

Healthy Salivary Flow as the Oral Cavity’s Protective System

Baseline saliva clears debris, buffers acid, and remineralizes enamel.

• 0.3–0.4: Normal unstimulated flow (mL/min baseline)
• 1–2: Stimulated flow (mL/min chewing)
• ~1–1.5 L: Daily saliva volume (produced per day)
• 6.7–7.4: Buffering pH range (bicarbonate system)

Protective functions of normal saliva

Placeholder: lubrication, buffering, antimicrobial, and remineralizing roles.

Placeholder: adequate flow keeps caries risk low under normal conditions.

Causes of Reduced Salivary Flow Rate

Medications and systemic disease commonly suppress gland output.

• 400+: Xerogenic drug classes (linked medications)
• ~0.1–0.4%: Sjögren’s prevalence (population)
• >50%: Radiotherapy impact (flow reduction)
• mild: Age-related decline (gland atrophy factor)

Major etiologies of hyposalivation

Placeholder: polypharmacy, autoimmune disease, radiation, dehydration.

Placeholder: many elderly patients take multiple xerogenic drugs.

Loss of Buffering Capacity and Oral Dryness

Falling bicarbonate output leaves plaque acid unneutralized.

• sharp: Bicarbonate drop (below 0.1 mL/min)
• <6.0: Resting oral pH (in xerostomia)
• high: Mucosal friction (reduced lubrication)
• prolonged: Clearance time (sugar/acid retention)

Buffering capacity and mucosal effects

Placeholder: bicarbonate, phosphate, and protein buffers weaken.

Placeholder: dryness accelerates plaque acidogenicity.

Rapid Caries Development in Xerostomic Patients

Demineralization outpaces repair, producing rampant caries patterns.

• 2–5×: Caries risk increase (vs. normal flow)
• cervical: Typical lesion sites (root surfaces)
• months: Onset speed (rampant progression)
• elevated: S. mutans levels (shift in flora)

Pattern and speed of xerostomic caries

Placeholder: cervical and root caries progress unusually fast.

Placeholder: untreated dry mouth can cause rampant decay.

Saliva Substitutes, Stimulants, and Preventive Care

Combined therapy restores wetting and lowers caries progression.

• pilocarpine: Sialogogue example (muscarinic agonist)
• gel/spray: Substitute types (artificial saliva)
• high-dose: Fluoride protocol (topical varnish)
• 3 months: Recall interval (high-risk patients)

Management strategy overview

Placeholder: substitutes, stimulants, fluoride, and diet control combine.

Placeholder: early management prevents rampant caries progression.